Andrew Baumgartner
Overview
Explore the profile of Andrew Baumgartner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
12
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baumgartner A, Robinson M, Ertekin-Taner N, Golde T, Jaydev S, Huang S, et al.
Commun Biol
. 2025 Feb;
8(1):279.
PMID: 39987247
The identification of microglia subtypes is important for understanding the role of innate immunity in neurodegenerative diseases. Current methods of unsupervised cell type identification assume a small noise-to-signal ratio of...
2.
Baumgartner A, Tirabassi J, Doyle M
Ann Fam Med
. 2024 Jul;
22(4):355.
PMID: 39038969
No abstract available.
3.
Baumgartner A, Robinson M, Golde T, Jaydev S, Huang S, Hadlock J, et al.
bioRxiv
. 2024 Jul;
PMID: 38979220
The identification of microglia subtypes is important for understanding the role of innate immunity in neurodegenerative diseases. Current methods of unsupervised cell type identification assume a small noise-to-signal ratio of...
4.
Wei Q, Mease P, Chiorean M, Iles-Shih L, Matos W, Baumgartner A, et al.
Lancet Digit Health
. 2024 Apr;
6(5):e309-e322.
PMID: 38670740
Background: In the context of immune-mediated inflammatory diseases (IMIDs), COVID-19 outcomes are incompletely understood and vary considerably depending on the patient population studied. We aimed to analyse severe COVID-19 outcomes...
5.
Girdhar K, Bendl J, Baumgartner A, Therrien K, Venkatesh S, Mathur D, et al.
Res Sq
. 2023 Oct;
PMID: 37886514
Non-coding variants increase risk of neuropsychiatric disease. However, our understanding of the cell-type specific role of the non-coding genome in disease is incomplete. We performed population scale (N=1,393) chromatin accessibility...
6.
Girdhar K, Bendl J, Baumgartner A, Therrien K, Venkatesh S, Mathur D, et al.
medRxiv
. 2023 Oct;
PMID: 37873320
Non-coding variants increase risk of neuropsychiatric disease. However, our understanding of the cell-type specific role of the non-coding genome in disease is incomplete. We performed population scale (N=1,393) chromatin accessibility...
7.
Wei Q, Mease P, Chiorean M, Iles-Shih L, Matos W, Baumgartner A, et al.
medRxiv
. 2023 Jul;
PMID: 37425752
Background: COVID-19 outcomes, in the context of immune-mediated inflammatory diseases (IMIDs), are incompletely understood. Reported outcomes vary considerably depending on the patient population studied. It is essential to analyse data...
8.
Duvvuri V, Baumgartner A, Molani S, Hernandez P, Yuan D, Roper R, et al.
Health Data Sci
. 2023 Feb;
2022.
PMID: 36817759
Background: Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin-II receptor blockers (ARB), the most commonly prescribed antihypertensive medications, counter renin-angiotensin-aldosterone system (RAAS) activation via induction of angiotensin-converting enzyme 2 (ACE2) expression. Considering...
9.
Stoll J, Ranahan M, Richbart M, Brennan-Taylor M, Taylor J, Brady L, et al.
Patient Educ Couns
. 2021 May;
104(11):2716-2723.
PMID: 33994020
Objective: Patient-driven deprescribing initiatives aim to increase patient knowledge and strengthen self-advocacy skills. This article describes the development of three animated videos designed to educate older adults about unsafe prescribing...
10.
Baumgartner A, Kunkes T, Clark C, Brady L, Monte S, Singh R, et al.
JMIR Hum Factors
. 2020 Aug;
7(3):e18103.
PMID: 32788157
Background: Despite making great strides in improving the treatment of diseases, the minimization of unintended harm by medication therapy continues to be a major hurdle facing the health care system....